Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection
ScD, MPH Catherine E Oldenburg, MD, PhD Benjamin A Pinsky, MPH, TM Jessica Brogdon, MS Cindi Chen, BS Kevin Ruder, BS Lina Zhong, BS Fanice Nyatigo, MPH Catherine A Cook, PhD Armin Hinterwirth, RN Elodie Lebas, MD, MPH Travis Redd, PhD, MPH; Travis C Porco, MD Thomas M Lietman, PhD, MPH Benjamin F Arnold, MD Thuy Doan
JAMA, doi:10.1001/jama.2021.11517
IMPORTANCE Azithromycin has been hypothesized to have activity against SARS-CoV-2. OBJECTIVE To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial of azithromycin vs matching placebo conducted from May 2020 through March 2021. Outpatients from the US were enrolled remotely via internet-based surveys and followed up for 21 days. Eligible participants had a positive SARS-CoV-2 diagnostic test result (nucleic acid amplification or antigen) within 7 days prior to enrollment, were aged 18 years or older, and were not hospitalized at the time of enrollment. Among 604 individuals screened, 297 were ineligible, 44 refused participation, and 263 were enrolled. Participants, investigators, and study staff were masked to treatment randomization. INTERVENTIONS Participants were randomized in a 2:1 fashion to a single oral 1.2-g dose of azithromycin (n = 171) or matching placebo (n = 92).
MAIN OUTCOMES AND MEASURES The primary outcome was absence of self-reported COVID-19 symptoms at day 14. There were 23 secondary clinical end points, including all-cause hospitalization at day 21. RESULTS Among 263 participants who were randomized (median age, 43 years; 174 [66%] women; 57% non-Hispanic White and 29% Latinx/Hispanic), 76% completed the trial. The trial was terminated by the data and safety monitoring committee for futility after the interim analysis. At day 14, there was no significant difference in proportion of participants who were symptom free (azithromycin: 50%; placebo: 50%; prevalence difference, 0%; 95% CI, -14% to 15%; P > .99). Of 23 prespecified secondary clinical end points, 18 showed no significant difference. By day 21, 5 participants in the azithromycin group had been hospitalized compared with 0 in the placebo group (prevalence difference, 4%; 95% CI, -1% to 9%; P = .16). CONCLUSIONS AND RELEVANCE Among outpatients with SARS-CoV-2 infection, treatment with a single dose of azithromycin compared with placebo did not result in greater likelihood of being symptom free at day 14. These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection.
Author Contributions: Drs Oldenburg and Arnold had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
References
Astale, Sata, Zerihun, Self-reported side effects following mass administration of azithromycin to eliminate trachoma in Amhara, Ethiopia: results from a region-wide population-based survey, Am J Trop Med Hyg,
doi:10.1038/s41564-020-0739-4Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2001282Cavalcanti, Zampieri, Rosa, Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2019014Doan, Worden, Hinterwirth, Macrolide and nonmacrolide resistance with mass azithromycin distribution, N Engl J Med,
doi:10.1056/NEJMoa2002606Gyselinck, Liesenborghs, Landeloos, Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial, Trials,
doi:10.1186/s13063-021-05033-xJohnston, Brown, Stewart, COVID-19 Early Treatment Study Team. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2021.100773Lachin, A review of methods for futility stopping based on conditional power, Stat Med,
doi:10.1002/sim.2151Lipsitch, Samore, Antimicrobial use and antimicrobial resistance: a population perspective, Emerg Infect Dis,
doi:10.3201/eid0804.010312Little, Agostino, Cohen, The prevention and treatment of missing data in clinical trials, N Engl J Med,
doi:10.1056/NEJMsr1203730Nehme, Braillard, Alcoba, COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings, Ann Intern Med,
doi:10.7326/M20-5926O'brien, Emerson, Hooper, Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review, Lancet Infect Dis,
doi:10.1016/S1473-3099(18)30444-4Oldenburg, Hinterwirth, Sié, Gut resistome after oral antibiotics in preschool children in Burkina Faso: a randomized, controlled trial, Clin Infect Dis,
doi:10.1093/cid/ciz455Recovery Collaborative, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet,
doi:10.1016/S0140-6736(21)00149-5Recovery Collaborative, Azithromycin in the treatment of patients admitted to the hospital with severe COVID-19: the COALITION II randomised clinical trial, Lancet,
doi:10.1016/S0140-6736(21)00149-5Sié, Dah, Bountogo, Adverse events and clinic visits following a single dose of oral azithromycin among preschool children: a randomized placebo-controlled trial, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-1002Trial, Group, Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet,
doi:10.1016/S0140-6736(21)00461-XDOI record:
{
"DOI": "10.1001/jama.2021.11517",
"ISSN": [
"0098-7484"
],
"URL": "http://dx.doi.org/10.1001/jama.2021.11517",
"author": [
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
},
{
"name": "Department of Ophthalmology, University of California, San Francisco"
},
{
"name": "Department of Epidemiology and Biostatistics, University of California, San Francisco"
}
],
"family": "Oldenburg",
"given": "Catherine E.",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Department of Pathology, Stanford University School of Medicine, Stanford, California"
},
{
"name": "Clinical Virology Laboratory, Stanford Health Care, Stanford, California"
},
{
"name": "Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford School of Medicine, Stanford, California"
}
],
"family": "Pinsky",
"given": "Benjamin A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Brogdon",
"given": "Jessica",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Chen",
"given": "Cindi",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Ruder",
"given": "Kevin",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Zhong",
"given": "Lina",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Nyatigo",
"given": "Fanice",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Cook",
"given": "Catherine A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Hinterwirth",
"given": "Armin",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
}
],
"family": "Lebas",
"given": "Elodie",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
},
{
"name": "Department of Ophthalmology, University of California, San Francisco"
}
],
"family": "Redd",
"given": "Travis",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
},
{
"name": "Department of Ophthalmology, University of California, San Francisco"
},
{
"name": "Department of Epidemiology and Biostatistics, University of California, San Francisco"
}
],
"family": "Porco",
"given": "Travis C.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
},
{
"name": "Department of Ophthalmology, University of California, San Francisco"
},
{
"name": "Department of Epidemiology and Biostatistics, University of California, San Francisco"
}
],
"family": "Lietman",
"given": "Thomas M.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
},
{
"name": "Department of Ophthalmology, University of California, San Francisco"
}
],
"family": "Arnold",
"given": "Benjamin F.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Francis I. Proctor Foundation, University of California, San Francisco"
},
{
"name": "Department of Ophthalmology, University of California, San Francisco"
}
],
"family": "Doan",
"given": "Thuy",
"sequence": "additional"
}
],
"container-title": "JAMA",
"container-title-short": "JAMA",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
7,
16
]
],
"date-time": "2021-07-16T15:30:44Z",
"timestamp": 1626449444000
},
"deposited": {
"date-parts": [
[
2021,
8,
10
]
],
"date-time": "2021-08-10T15:59:43Z",
"timestamp": 1628611183000
},
"indexed": {
"date-parts": [
[
2024,
9,
16
]
],
"date-time": "2024-09-16T15:54:53Z",
"timestamp": 1726502093596
},
"is-referenced-by-count": 93,
"issue": "6",
"issued": {
"date-parts": [
[
2021,
8,
10
]
]
},
"journal-issue": {
"issue": "6",
"published-print": {
"date-parts": [
[
2021,
8,
10
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://jamanetwork.com/journals/jama/articlepdf/2782166/jama_oldenburg_2021_oi_210081_1628008964.95494.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "10",
"original-title": [],
"page": "490",
"prefix": "10.1001",
"published": {
"date-parts": [
[
2021,
8,
10
]
]
},
"published-print": {
"date-parts": [
[
2021,
8,
10
]
]
},
"publisher": "American Medical Association (AMA)",
"reference": [
{
"DOI": "10.1002/rmv.2163",
"article-title": "Azithromycin in viral infections.",
"author": "Oliver",
"doi-asserted-by": "crossref",
"issue": "2",
"journal-title": "Rev Med Virol",
"key": "joi210081r1",
"volume": "31",
"year": "2021"
},
{
"DOI": "10.1016/S1473-3099(18)30444-4",
"article-title": "Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review.",
"author": "O’Brien",
"doi-asserted-by": "publisher",
"first-page": "e14",
"issue": "1",
"journal-title": "Lancet Infect Dis",
"key": "joi210081r2",
"volume": "19",
"year": "2019"
},
{
"DOI": "10.1016/S0140-6736(21)00461-X",
"article-title": "Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.",
"author": "PRINCIPLE Trial Collaborative Group",
"doi-asserted-by": "publisher",
"first-page": "1063",
"issue": "10279",
"journal-title": "Lancet",
"key": "joi210081r3",
"volume": "397",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2019014",
"article-title": "Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19.",
"author": "Cavalcanti",
"doi-asserted-by": "publisher",
"first-page": "2041",
"issue": "21",
"journal-title": "N Engl J Med",
"key": "joi210081r4",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1016/S0140-6736(21)00149-5",
"article-title": "Azithromycin in the treatment of patients admitted to the hospital with severe COVID-19: the COALITION II randomised clinical trial.",
"author": "RECOVERY Collaborative Group",
"doi-asserted-by": "publisher",
"first-page": "605",
"issue": "10274",
"journal-title": "Lancet",
"key": "joi210081r5",
"volume": "397",
"year": "2021"
},
{
"DOI": "10.1016/j.eclinm.2021.100773",
"article-title": "Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial.",
"author": "Johnston",
"doi-asserted-by": "crossref",
"journal-title": "EClinicalMedicine",
"key": "joi210081r6",
"volume": "33",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2001282",
"article-title": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.",
"author": "Cao",
"doi-asserted-by": "publisher",
"first-page": "1787",
"issue": "19",
"journal-title": "N Engl J Med",
"key": "joi210081r7",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1186/s13063-021-05033-x",
"article-title": "Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial.",
"author": "Gyselinck",
"doi-asserted-by": "publisher",
"first-page": "126",
"issue": "1",
"journal-title": "Trials",
"key": "joi210081r8",
"volume": "22",
"year": "2021"
},
{
"DOI": "10.1056/NEJMsr1203730",
"article-title": "The prevention and treatment of missing data in clinical trials.",
"author": "Little",
"doi-asserted-by": "publisher",
"first-page": "1355",
"issue": "14",
"journal-title": "N Engl J Med",
"key": "joi210081r9",
"volume": "367",
"year": "2012"
},
{
"DOI": "10.1002/(ISSN)1097-0258",
"article-title": "A review of methods for futility stopping based on conditional power.",
"author": "Lachin",
"doi-asserted-by": "publisher",
"first-page": "2747",
"issue": "18",
"journal-title": "Stat Med",
"key": "joi210081r10",
"volume": "24",
"year": "2005"
},
{
"DOI": "10.1016/S0140-6736(21)00149-5",
"article-title": "Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.",
"author": "RECOVERY Collaborative Group",
"doi-asserted-by": "publisher",
"first-page": "605",
"issue": "10274",
"journal-title": "Lancet",
"key": "joi210081r11",
"volume": "397",
"year": "2021"
},
{
"DOI": "10.1001/jama.2020.6771",
"article-title": "Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection.",
"author": "Spinato",
"doi-asserted-by": "publisher",
"first-page": "2089",
"issue": "20",
"journal-title": "JAMA",
"key": "joi210081r12",
"volume": "323",
"year": "2020"
},
{
"DOI": "10.7326/M20-5926",
"article-title": "COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings.",
"author": "Nehme",
"doi-asserted-by": "publisher",
"first-page": "723",
"issue": "5",
"journal-title": "Ann Intern Med",
"key": "joi210081r13",
"volume": "174",
"year": "2021"
},
{
"article-title": "Adverse events and clinic visits following a single dose of oral azithromycin among preschool children: a randomized placebo-controlled trial.",
"author": "Sié",
"first-page": "1137",
"issue": "3",
"journal-title": "Am J Trop Med Hyg",
"key": "joi210081r14",
"volume": "104",
"year": "2020"
},
{
"DOI": "10.4269/ajtmh.2011.11-0056",
"article-title": "Adverse events after mass azithromycin treatments for trachoma in Ethiopia.",
"author": "Ayele",
"doi-asserted-by": "publisher",
"first-page": "291",
"issue": "2",
"journal-title": "Am J Trop Med Hyg",
"key": "joi210081r15",
"volume": "85",
"year": "2011"
},
{
"DOI": "10.4269/ajtmh.18-0781",
"article-title": "Self-reported side effects following mass administration of azithromycin to eliminate trachoma in Amhara, Ethiopia: results from a region-wide population-based survey.",
"author": "Astale",
"doi-asserted-by": "publisher",
"first-page": "696",
"issue": "3",
"journal-title": "Am J Trop Med Hyg",
"key": "joi210081r16",
"volume": "100",
"year": "2019"
},
{
"DOI": "10.1038/s41564-020-0739-4",
"article-title": "Antimicrobial resistance in the age of COVID-19.",
"doi-asserted-by": "publisher",
"first-page": "779",
"issue": "6",
"journal-title": "Nat Microbiol",
"key": "joi210081r17",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1016/S2666-5247(21)00039-2",
"article-title": "COVID-19 drug practices risk antimicrobial resistance evolution.",
"author": "Afshinnekoo",
"doi-asserted-by": "publisher",
"first-page": "e135",
"issue": "4",
"journal-title": "Lancet Microbe",
"key": "joi210081r18",
"volume": "2",
"year": "2021"
},
{
"DOI": "10.3201/eid0804.010312",
"article-title": "Antimicrobial use and antimicrobial resistance: a population perspective.",
"author": "Lipsitch",
"doi-asserted-by": "publisher",
"first-page": "347",
"issue": "4",
"journal-title": "Emerg Infect Dis",
"key": "joi210081r19",
"volume": "8",
"year": "2002"
},
{
"DOI": "10.1056/NEJMoa2002606",
"article-title": "Macrolide and nonmacrolide resistance with mass azithromycin distribution.",
"author": "Doan",
"doi-asserted-by": "publisher",
"first-page": "1941",
"issue": "20",
"journal-title": "N Engl J Med",
"key": "joi210081r20",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1093/cid/ciz455",
"article-title": "Gut resistome after oral antibiotics in preschool children in Burkina Faso: a randomized, controlled trial.",
"author": "Oldenburg",
"doi-asserted-by": "publisher",
"first-page": "525",
"issue": "3",
"journal-title": "Clin Infect Dis",
"key": "joi210081r21",
"volume": "70",
"year": "2020"
}
],
"reference-count": 21,
"references-count": 21,
"relation": {
"has-review": [
{
"asserted-by": "object",
"id": "10.3410/f.740482290.793588147",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://jamanetwork.com/journals/jama/fullarticle/2782166"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [
"A Randomized Clinical Trial"
],
"title": "Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection",
"type": "journal-article",
"volume": "326"
}
